Exelixis, Inc. (BVMF:E2XE34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 93.36B +61.4% |
| Revenue (ttm) | 12.93B +9.1% |
| Net Income | 4.58B +30.6% |
| EPS | 9.11 +40.9% |
| Shares Out | n/a |
| PE Ratio | 15.77 |
| Forward PE | 16.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Open | 143.40 |
| Previous Close | 137.40 |
| Day's Range | 143.40 - 143.40 |
| 52-Week Range | 98.24 - 143.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial numbers in USD Financial StatementsNews
Exelixis price target raised to $60 from $53 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $60 from $53 and keeps an Equal Weight rating on the shares.
Exelixis price target raised to $60 from $54 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Exelixis (EXEL) to $60 from $54 and keeps a Hold rating on the shares. The company reported Q3 EPS with…
Exelixis price target raised to $76 from $55 at TD Cowen
TD Cowen raised the firm’s price target on Exelixis (EXEL) to $76 from $55 and keeps a Buy rating on the shares. The firm said Q3 cabo franchise sales of…
Exelixis price target raised to $54 from $49 at Barclays
Barclays raised the firm’s price target on Exelixis (EXEL) to $54 from $49 and keeps an Equal Weight rating on the shares.
Exelixis Earnings Call Transcript: Q3 2026
Q3 revenue reached $659M as CABO franchise sales grew 11% YoY in the U.S. and globally. Zanza advanced across pivotal programs, with STELLAR-303 review underway and key 2027 readouts ahead.
Exelixis Earnings release: Q3 2026
Exelixis released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Exelixis Quarterly report: Q3 2026
Exelixis has published its Q3 2026 quarterly earnings report on October 29, 2026.
Exelixis Slides: Q3 2026
Exelixis has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Exelixis reports Q3 adjusted EPS 94c, consensus 80c
Reports Q3 revenue $658.7M, consensus $646.51M. “Exelixis (EXEL) continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing ...
Exelixis sees FY26 revenue $2.5B-$2.55B, consensus $2.55B
16:37 EDT Exelixis (EXEL) sees FY26 revenue $2.5B-$2.55B, consensus $2.55B
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives...
Exelixis Rises with Earnings on Tap
Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.
Exelixis price target raised to $65 from $55 at Citizens
Citizens raised the firm’s price target on Exelixis (EXEL) to $65 from $55 and keeps an Outperform rating on the shares. Overall, the firm remains confident in Exelixis, especially given…
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. A...
Exelixis price target raised to $51 from $45 at RBC Capital
RBC Capital raised the firm’s price target on Exelixis (EXEL) to $51 from $45 and keeps a Sector Perform rating on the shares. The firm’s deep dive look into the…
Exelixis price target lowered to $45 from $46 at RBC Capital
RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $45 from $46 and keeps a Sector Perform rating on the shares as part of a broader research note…
Exelixis price target raised to $54 from $52 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Exelixis (EXEL) to $54 from $52 and keeps a Hold rating on the shares as part of a broader research…
Exelixis Shares Rising on CABOMETYX Revenue
Big Money pushes Exelixis, Inc. (EXEL) shares higher by 149% since 2017.
Exelixis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strategy centers on expanding cabozantinib and building zanzalintinib into a second franchise, with CRC launch preparation continuing toward a March 3 PDUFA date. Curated data, selective AI use, and disciplined internal and external R&D guide investment.
Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair
William Blair is “surprised” by the three-month delay of the PDUFA date for Exelixis (EXEL)’ new drug application for zanzalintinib in combination with atezolizumab, but believes the risk of rejection...
U.S. FDA extends review of Exelixis' cancer drug
The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
Exelixis says FDA extends review period for zanzalintinib NDA by three months
Exelixis (EXEL) announced that on September 10, the U.S. Food and Drug Administration notified Exelixis that it had extended the review period for Exelixis’ new drug application for zanzalintinib, in…
Exelixis Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding product franchises, especially CABOMETYX and zanzalintinib, across multiple indications and modalities. CABOMETYX shows durable growth in RCC and NETs, while zanzalintinib is positioned for major opportunities in CRC and RCC. AI-driven tools are enhancing commercial and R&D efficiency.
Adagene announces $2M milestone payment from Exelixis
Adagene (ADAG) announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis (EXEL). The milestone achievement is related to a preclinical milestone event f...
Exelixis Transcript: Wells Fargo 21st Annual Healthcare Conference
CABO's growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. Zanza is poised for immediate CRC launch, supported by strong clinical data and expanded sales force. Strategic focus includes pipeline expansion, business development, and balanced capital allocation.